GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark to divest select Anti-Allergy brands to Dr Reddy's in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its 'Ryaltris' Launch GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the third year in a row As refinancing risks ease, S&P; affirms Glenmark Pharma's 'BB-' rating
The rating agency has a stable outlook on Glenmark Pharma's rating and also removed it from 'CreditWatch' GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating
Sub:- Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 - S&P; Global Ratings With reference to the subject mentioned above, kindly find enclosed rating research update issued by S&P; Global Ratings for your reference.
Study shows Favipiravir provides multiple benefits in COVID-19 treatment: Glenmark Pharmaceuticals
Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby halting the virus's replication cycle. This helps control the multiplication of the virus and prevents its spread in the patient, Glenmark said. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")
We wish to inform you that Glenmark Pharmaceuticals Limited ('Company') has issued a notice of optional redemption to the holders of U.S. $200 million 4.5% Senior Notes due 2021 ('Notice') listed on the Singapore Exchange Securities Trading Limited, in accordance with the terms of the Indenture dated as of August 1, 2016 (as amended, supplemented, waived or otherwise modified from time to time), between, among others, the Company and Citicorp International Limited, as trustee. Copy of the Notice is attached herewith. Capitalised or other terms used but not defined herein shall, unless the context otherwise requires, have the meanings as set out in the Notice. We request you to kindly take this intimation on record and to treat the same as compliance with the applicable provisions of the SEBI LODR.
Buy Glenmark Pharmaceuticals: target of Rs 635: ICICI Direct
ICICI Direct is bullish on Glenmark Pharmaceuticals recommended buy rating on the stock with a target price of Rs 635 in its research report dated November 09, 2020. Glenmark Pharmaceuticals gets US FDA approval for Tacrolimus Capsules USP
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg, the generic version of Prograf1 Capsules, 0.5 mg, 1 mg and 5 mg, of Astellas Pharm US, Inc.According to IQVIATM sales data for the 12 month period ending September 2020, the Prograf Capsules, 0.5 mg, 1 mg and 5 mg market2 achieved annual sales of approximately USD 286.8 million*.Glenmark's current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.1 All brand names and trademarks are the property of their respective owners.2 Market includes brand and all available therapeutic equivalents* IQVIATM National Sales . GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg